PSEN2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL33171	1.00	20/20
SCHEMBL137789	1.00	20/20
SCHEMBL139302	1.00	20/20
Mrk-560 (SCHEMBL237758)	1.00	20/20
Mrk-560 (SCHEMBL237759)	1.00	20/20
Mrk-560 (SCHEMBL237760)	1.00	20/20
SCHEMBL136503	0.76	20/20
SCHEMBL154957	0.66	20/20
SCHEMBL138898	0.66	20/20
SCHEMBL139605	0.66	20/20
Hydrochloric Acid (SCHEMBL154119)	0.65	20/20
SCHEMBL139065	0.64	20/20
SCHEMBL151407	0.62	20/20
SCHEMBL138968	0.61	20/20
SCHEMBL139498	0.60	20/20
SCHEMBL154717	0.58	20/20
SCHEMBL139470	0.58	20/20
SCHEMBL139515	0.58	20/20
SCHEMBL139460	0.58	20/20
SCHEMBL155625	0.57	20/20

Clinical trials — most relevant to PSEN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)	PHASE4	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.	PHASE2/PHASE3	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	PHASE2/PHASE3	RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	PHASE2/PHASE3	RECRUITING
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort	PHASE2	COMPLETED
Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study	PHASE2	COMPLETED
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants	PHASE1	ACTIVE_NOT_RECRUITING
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease	PHASE1	COMPLETED
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease	PHASE1	COMPLETED
Exploratory and Safety Study of [F-18]W372	EARLY_PHASE1	COMPLETED
Apolipoprotein E Gene and Functional MRI	nan	COMPLETED
Central and Systemic Inflammation in Alzheimer's Disease	nan	COMPLETED
Late Onset Alzheimer's Disease	nan	RECRUITING
The Evaluation and Follow-up of Individuals With Memory Disorder	nan	COMPLETED
Prognostic Observation of Posterior Reversible Encephalopathy Syndrome	nan	UNKNOWN
The Genetic Characterization of Dementia	nan	COMPLETED
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease	nan	WITHDRAWN
The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition	nan	COMPLETED
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)	nan	COMPLETED
The Signature of Alzheimer's Disease in Subjective Cognitive Decline	nan	RECRUITING
China Cognition and Aging Study	nan	RECRUITING
Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome	nan	UNKNOWN
The Swedish BioFINDER - Memory Clinic Study	nan	RECRUITING
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients	nan	COMPLETED
Identification of New FTLD Genes	nan	UNKNOWN
Dominantly Inherited Alzheimer Network (DIAN)	nan	RECRUITING
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)	nan	COMPLETED
Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSEN2 binder may also engage these)

Protein	Name	Similarity
Q0MS45	—	1.000	Q0MS45 →
P79801	—	1.000	P79801 →
O88777	—	1.000	O88777 →
Q5RCN9	—	1.000	Q5RCN9 →
Q61144	—	1.000	Q61144 →
Q9XT96	—	1.000	Q9XT96 →
Q6RH31	—	1.000	Q6RH31 →
Q90ZE4	—	1.000	Q90ZE4 →
Q5R780	—	0.999	Q5R780 →
Q90X07	—	0.998	Q90X07 →
Q9W6T7	—	0.997	Q9W6T7 →
P79802	—	0.997	P79802 →
O12976	—	0.997	O12976 →
P49769	—	0.996	P49769 →
O12977	—	0.995	O12977 →
Q8HXW5	—	0.995	Q8HXW5 →
PSEN1	Presenilin-1	0.995	landscape →
P52166	—	0.994	P52166 →
O64668	—	0.993	O64668 →
P97887	—	0.992	P97887 →
Q4JIM4	—	0.991	Q4JIM4 →
Q9SIK7	—	0.989	Q9SIK7 →
Q9XT97	—	0.988	Q9XT97 →
O02100	—	0.988	O02100 →
O02194	—	0.987	O02194 →
Q6NZ21	—	0.987	Q6NZ21 →
F1RAX4	—	0.986	F1RAX4 →
Q28FG4	—	0.986	Q28FG4 →
O95477	—	0.985	O95477 →
B4HEB1	—	0.985	B4HEB1 →